Study guide
Non-Insulin Glucose-Lowering Agents
CDCES Certified Diabetes Care and Education Specialist
Track your progress as you read
Finished sections get a check mark.
1 Introduction & the CDCES Exam
About the CDCES Credential & Current Exam Facts The July 2024 Exam Content Outline & Domain Weights The ADCES7 Self-Care Behaviors Framework
2 Pathophysiology, Classification & Diagnosis
Normal Glucose Regulation and the Pathophysiology of T1DM and T2DM Classification and Diagnostic Criteria Risk Factors and Primary Prevention Treatment Goals and Glycemic Targets
3 Assessment: History, Physical & Data
Health History & Diabetes-Specific Physical Assessment Interpreting Diabetes Measures & Laboratory Data Social Determinants of Health & Psychosocial Wellbeing
4 Assessing Self-Management & Learning
Assessing Self-Management Behaviors & Knowledge Assessing Technology Use, Problem-Solving & Risk-Reduction Behaviors Assessing Learning: Goals, Readiness to Change & Literacy Learning Considerations & Barriers
5 Developing the Education & Care Plan
Developing the Individualized Education/Care Plan Instructional Methods & Person-Centered Teaching Strategies SMART Goals, Behavior-Change Theory & Motivational Interviewing
6 Nutrition Therapy
Nutrition Recommendations & Eating Patterns Carbohydrate Counting & Insulin-Food Timing Fats, Protein, Alcohol & Dietary Supplements Food Labels, Weight Management & Special Nutrition Considerations
7 Physical Activity
Physical Activity Recommendations, Benefits, Challenges & Safety Activity Planning with FITT and Adjusting for Planned & Unplanned Activity
8 Pharmacologic Therapy
Insulin — Types, Pharmacokinetics & Delivery Systems Non-Insulin Glucose-Lowering Agents Guideline-Based Medication Selection Medication Titration & Immunizations for People with Diabetes
9 Monitoring
Glucose Monitoring: SMBG, CGM & Time in Range A1C and Ketone Monitoring Cardiometabolic and Organ System Monitoring
10 Acute Complications
Hypoglycemia Hyperglycemia, DKA, and HHS
11 Chronic Complications
Screening Schedules and Microvascular Disease Macrovascular Disease and Lower-Extremity Foot Care Infections, Dental Disease, Sexual Dysfunction, and Other Comorbidities
12 Special Situations & Populations
Sick-Day Management, Surgery, Travel & Emergency Preparedness Special Populations Across the Lifespan Preconception, Pregnancy, Postpartum & Gestational Diabetes Daily Living, Psychosocial Wellbeing & Safety
13 Evaluation & Documentation
Evaluating Intervention Effectiveness & Outcomes Documentation, Plan Revision & Referral
14 Standards, Guidelines & Professional Practice
National Standards for DSMES and the National DPP Applying Evidence-Based Practice Guidelines Population Health, Health Equity & Advocacy
Non-Insulin Glucose-Lowering Agents
Key Takeaways Explain This Topic AI
Metformin is contraindicated at an eGFR below 30 mL/min/1.73 m² and is not recommended for initiation at an eGFR of 30-45 mL/min/1.73 m².
All GLP-1 receptor agonists and dual GIP/GLP-1 agonists (tirzepatide) carry a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma or MEN2.
SGLT2 inhibitors can cause euglycemic DKA, in which ketoacidosis occurs despite a blood glucose under 200 mg/dL, so ketones must be checked whenever DKA is suspected.
Sulfonylureas carry the highest hypoglycemia risk among oral glucose-lowering agents and also cause weight gain.
Pioglitazone (a thiazolidinedione) is contraindicated in NYHA class III-IV heart failure due to fluid retention and also increases fracture risk.
Last updated: July 2026
Metformin: First-Line Therapy
Metformin, a biguanide, remains first-line pharmacologic therapy for most people with type 2 diabetes because of its glycemic efficacy, weight neutrality to modest weight loss, low hypoglycemia risk when used alone, favorable cardiovascular safety record, and low cost.
Mechanism: primarily reduces hepatic glucose production, with a modest additional improvement in peripheral insulin sensitivity.
GI effects: the most common adverse effect, occurring in roughly 20-30% of new users (nausea, diarrhea, abdominal discomfort). These effects typically diminish over days to weeks and are mitigated by starting at a low dose, titrating gradually, taking the dose with food, and/or using an extended-release formulation.
Vitamin B12 deficiency: long-term metformin use interferes with the calcium-dependent uptake of the intrinsic-factor-B12 complex in the ileum. A clinically meaningful biochemical deficiency develops in roughly 5-10% of long-term users, more often at higher doses. Periodic B12 monitoring is recommended, particularly at doses of 1,500 mg/day or greater, with prolonged use, or if anemia or peripheral neuropathy symptoms develop.
Lactic acidosis: rare but serious; risk rises with the degree of renal impairment because metformin is cleared renally, essentially unchanged.
★ Renal dosing rule: metformin is contraindicated at an eGFR below 30 mL/min/1.73 m² . Initiation is not recommended for an eGFR of 30-45 mL/min/1.73 m². Around iodinated contrast administration, metformin should be held and renal function rechecked about 48 hours later before resuming in anyone with an eGFR of 30-60, hepatic impairment, alcohol use disorder, or heart failure; at an eGFR of 30 or above with no acute kidney injury, metformin can generally be continued through contrast administration.
Non-Insulin Agent Comparison
Class Examples Key Mechanism Notable Effects / Safety
Biguanide Metformin Reduces hepatic glucose production GI upset, B12 deficiency, rare lactic acidosis; contraindicated eGFR <30
GLP-1 receptor agonist Exenatide, liraglutide, dulaglutide, semaglutide Glucose-dependent insulin release, reduced glucagon, slowed gastric emptying Weight loss, GI effects, pancreatitis caution, boxed warning: personal/family history of MTC or MEN2
Dual GIP/GLP-1 receptor agonist Tirzepatide Combined incretin agonism Greater weight loss than GLP-1-only agents; same GI, pancreatitis, and MTC/MEN2 boxed warning
SGLT2 inhibitor Canagliflozin, dapagliflozin, empagliflozin Blocks renal glucose reabsorption, causing glucosuria CV, heart-failure, and renal benefit; euglycemic DKA risk; genital mycotic infection; canagliflozin carries a separate amputation boxed warning
DPP-4 inhibitor Sitagliptin, saxagliptin, linagliptin, alogliptin Prolongs endogenous incretin (GLP-1/GIP) activity Weight-neutral, low hypoglycemia risk alone; arthralgia; saxagliptin and alogliptin increase heart-failure hospitalization risk
Sulfonylurea Glipizide, glimepiride, glyburide Stimulates insulin secretion from beta cells, independent of glucose level Highest hypoglycemia risk among oral agents; weight gain; glyburide carries the highest risk, especially in older adults or renal impairment
Thiazolidinedione (TZD) Pioglitazone PPAR-gamma agonist, increases peripheral insulin sensitivity Fluid retention/edema, contraindicated in NYHA class III-IV heart failure, increased fracture risk, weight gain
★ GLP-1 Receptor Agonists and Dual GIP/GLP-1 Agents
These incretin-based therapies produce substantial weight loss — greatest with the dual GIP/GLP-1 agonist tirzepatide — while improving glycemic control, and several GLP-1 receptor agonists with dedicated cardiovascular outcome trials reduce major adverse cardiovascular events in people with established ASCVD. Gastrointestinal effects (nausea, vomiting, diarrhea, constipation) are dose-dependent and common; doses are escalated slowly over weeks specifically to improve tolerability, and symptoms typically improve over time. Because these agents slow gastric emptying, they warrant caution — and are a relative contraindication — in people with a history of severe gastroparesis. They should not be initiated in anyone with a history of pancreatitis and should be discontinued if pancreatitis is suspected during treatment.
All GLP-1 receptor agonists and dual GIP/GLP-1 agonists carry an FDA boxed warning against use in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). This warning is based on thyroid C-cell tumors observed in rodent studies; a causal link in humans has not been established, but the contraindication applies regardless.
★ SGLT2 Inhibitors
SGLT2 inhibitors lower glucose independent of insulin by blocking glucose reabsorption in the proximal renal tubule, producing glucosuria. Beyond glycemic control, they reduce heart-failure hospitalization and slow progression of chronic kidney disease — benefits recognized independent of baseline A1C or metformin use. Their leading safety concerns are genital mycotic infections (the most common adverse effect, mitigated with hygiene counseling) and euglycemic diabetic ketoacidosis (euglycemic DKA) — DKA occurring with a near-normal or only mildly elevated glucose. Because SGLT2 inhibitor-associated DKA commonly presents with glucose under 200 mg/dL, glucose level alone cannot rule out DKA; ketones must be checked whenever a person on an SGLT2 inhibitor has DKA symptoms such as nausea, vomiting, abdominal pain, or malaise. Recognized risk factors include prolonged fasting, very-low-carbohydrate diets, dehydration, excess alcohol use, acute illness, surgery, and insulin under-dosing or omission — the CDCES teaches patients to hold SGLT2 inhibitors before scheduled surgery and during acute illness with reduced oral intake.
DPP-4 Inhibitors, Sulfonylureas, and TZDs
DPP-4 inhibitors are weight-neutral with a low hypoglycemia risk when used alone, but their cardiovascular safety is not uniform across the class: saxagliptin and alogliptin increase the risk of heart-failure hospitalization, while sitagliptin and linagliptin have not shown this signal in dedicated cardiovascular outcome trials. Sulfonylureas carry the highest hypoglycemia risk of any oral agent because they stimulate insulin secretion independent of glucose level, plus consistent weight gain; glyburide is the highest-risk agent in the class, particularly in older adults or renal impairment. Pioglitazone , the primary TZD in current use, improves peripheral insulin sensitivity but causes fluid retention that is contraindicated in NYHA class III-IV heart failure, along with an increased fracture risk and weight gain.
Two testable distinctions: "weight neutral" (DPP-4 inhibitors) is not the same as "weight loss" (GLP-1 RA, dual GIP/GLP-1, SGLT2i), and metformin's renal cutoff is a hard contraindication at eGFR <30, while the 30-45 range is only a "do not initiate" caution rather than an absolute contraindication for someone already stable on the drug.